(Q42202767)

18 October 2017

title

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study (English)

1 reference

18 October 2017

1 reference

1 reference

1 reference

1 reference

Jia-Horng Kao

20

0 references

Guido Gerken

10

object named as

Guido Gerken

1 reference

18 October 2017

2

Stanislas Pol

1 reference

18 October 2017

4

Patrick Marcellin

1 reference

18 October 2017

Michael Manns

1

1 reference

18 October 2017

Ira M Jacobson

3

1 reference

18 October 2017

Stuart C Gordon

5

1 reference

18 October 2017

Cheng-Yuan Peng

6

1 reference

18 October 2017

Ting-Tsung Chang

7

1 reference

18 October 2017

Gregory T Everson

8

1 reference

18 October 2017

Jeong Heo

9

1 reference

18 October 2017

Boris Yoffe

11

1 reference

18 October 2017

William J Towner

12

1 reference

18 October 2017

Marc Bourliere

13

1 reference

18 October 2017

Sophie Metivier

14

1 reference

18 October 2017

Chi-Jen Chu

15

1 reference

18 October 2017

William Sievert

16

1 reference

18 October 2017

Jean-Pierre Bronowicki

17

1 reference

18 October 2017

Dominique Thabut

18

1 reference

18 October 2017

Youn-Jae Lee

19

1 reference

18 October 2017

Fiona McPhee

21

1 reference

18 October 2017

Justin Kopit

22

1 reference

18 October 2017

Patricia Mendez

23

1 reference

18 October 2017

Misti Linaberry

24

1 reference

18 October 2017

Eric Hughes

25

1 reference

18 October 2017

Stephanie Noviello

26

1 reference

18 October 2017

HALLMARK-DUAL Study Team

27

1 reference

18 October 2017

language of work or name

English

0 references

publication date

28 July 2014

1 reference

18 October 2017

1 reference

18 October 2017

volume

384

1 reference

18 October 2017

issue

9954

1 reference

18 October 2017

page(s)

1597-1605

1 reference

Distribution of hepatitis C virus genotypes in a diverse US integrated health care population

18 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

The global health burden of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Sofosbuvir for previously untreated chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Novel therapies for hepatitis C - one pill fits all?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Racial differences in hepatitis C treatment eligibility

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

New hepatitis C therapies: the toolbox, strategies, and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Antiviral activity and resistance of HCV NS5A replication complex inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Preliminary study of two antiviral agents for hepatitis C genotype 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Future treatment of patients with HCV cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

APASL consensus statements and management algorithms for hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961059-X

7 January 2021

10.1016/S0140-6736(14)61059-X

Identifiers

DOI

1 reference

18 October 2017

1 reference